Chiesi, Lundbeck and Li-Cor Biosciences scored exits as the oncology therapy developer floated in an upsized $75.6m initial public offering.
US-based cancer therapy developer Aura Biosciences went public on Friday in a $75.6m initial public offering representing an exit for pharmaceutical firms Chiesi Group, Li-Cor Biosciences and Lundbeck.
The company increased the number of shares in the offering from 5 million to 5.4 million and priced them at the foot of the IPO’s $14 to $16 range. They closed at $15.28 on Aura’s first day of trading on the Nasdaq Global Market on Friday, giving it a market cap of…
